Barclays’s Ocean Biomedical, Inc. Common Stock OCEA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-478
Closed -$583 5535
2024
Q2
$583 Sell
478
-5,748
-92% -$9.81K ﹤0.01% 4705
2024
Q1
$23.6K Sell
6,226
-6,428
-51% -$12.1K ﹤0.01% 4736
2023
Q4
$8.35K Buy
12,654
+11,276
+818% +$15.5K ﹤0.01% 4984
2023
Q3
$5.37K Sell
1,378
-354
-20% -$1.63K ﹤0.01% 4375
2023
Q2
$10.4K Sell
1,732
-651
-27% -$3.82K ﹤0.01% 4215
2023
Q1
$15.8K Buy
+2,383
New +$20.1K ﹤0.01% 4693

Other funds holding OCEA

Barclays's OCEA Position: Q3 2024 in Review

Barclays sold out of Ocean Biomedical, Inc. Common Stock (OCEA) in Q3 2024, closing a stake of 478 shares — an estimated $583 sold.

Barclays first reported a position in OCEA in Q1 2023 and held it in 6 quarters. The position peaked at $23.6K in Q1 2024. 21 funds tracked by Wall St. Rank hold OCEA as of Q3 2024.

  • Barclays reported no remaining Ocean Biomedical, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Barclays sold 478 Ocean Biomedical, Inc. Common Stock shares in Q3 2024, an estimated $583.
  • Barclays first reported a position in Ocean Biomedical, Inc. Common Stock in Q1 2023 and held it in 6 quarters.
  • Barclays's Ocean Biomedical, Inc. Common Stock position peaked at $23.6K in Q1 2024.
  • 21 funds tracked by Wall St. Rank held Ocean Biomedical, Inc. Common Stock as of Q3 2024.

Based on Barclays's 13F filing for Q3 2024, filed 15 Nov 2024.